News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hua Medicine Reports Strong Results For Early Diabetes Drug Trial


3/20/2014 12:59:37 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

March 20, 2014 -- Hua Medicine of Shanghai announced it will start a Phase Ib trial of its glucokinase activator (GKA) treatment for type 2 diabetes. In the Phase Ia trial, HMS5552 produced positive results in healthy volunteers. Because of the excellent early results, Hua thinks HMS5552 may be a best-in-class candidate. The Phase Ib trial will test the drug in type 2 diabetics. Hua, which in-licensed the second generation GKA drug from Roche, holds global rights to HMS5552. More details....

Stock Symbol: (SIX: ROG)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES